<DOC>
	<DOCNO>NCT01015326</DOCNO>
	<brief_summary>Epidermal Growth Factor Receptor Inhibitors ( EGFRI ) associate skin toxicity . Clinical experience suggest skin toxicity interfere health relate quality life ( HRQL ) may interfere treatment adherence . No systematic investigation EGFRI-associated dermatologic toxicity impact HRQL report . No patient-reported outcome measure exist capture unique concern oncology patient experience EGFRI-associated dermatologic toxicity . The purpose study develop patient-reported outcome measure ass dermatologic-related symptom burden health-related quality life among patient receive EGFRI , develop grade system EGFRI-associated dermatologic toxicity .</brief_summary>
	<brief_title>Development Dermatology-related Quality Life Assessment Patients Treated With Epidermal Growth Factor Receptor ( EGFR ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Mitogens</mesh_term>
	<criteria>Undergoing antiEGFR cancer therapy Over 18 year old Unable complete questionnaire Unable follow instruction give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>EGFRI</keyword>
	<keyword>HRQL</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Development standardize HRQL instrument anti-EGFR therapy induce</keyword>
</DOC>